Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(10):747-748; doi:10.1093/jnci/djk217
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Finkelstein, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Finkelstein, J. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

NEWS

Proposed FDA Conflict-of-Interest Guidelines Get Lukewarm Reception

Joel B. Finkelstein

The first 10% of the full text of this article appears below.

The U.S. Food and Drug Administration has shed new light on the process of vetting advisory committee members, but several experts said that recently proposed financial guidelines do not go far enough to weed out conflicts of interest.

The FDA has come under increasing pressure from Congress to implement stricter oversight of regulated products throughout the approval process. Among several currently pending proposals is legislation that would require that the agency publish the conflict-of-interest information for its advisors at least 30 days before committee meetings, under most circumstances.

The FDA's proposed guidelines leapfrog those congressional efforts by establishing a financial cutoff, said Bill Vaughan, a senior policy analyst for Consumers Union, publisher of Consumer Reports.

. . . [Full Text of this Article]

Breaking the Cycle

A Step Forward


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?